secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metsera, Inc. (—)
CIK:        0002040807
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-280387
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer completes acquisition of Metsera for $65.60/share plus CVRs
------------------------------------------------------------------

- Total consideration: $65.60 cash per share plus one non-tradable CVR per share with up to $20.65 in milestone payments.
- CVR milestones: $4.60 for Phase 3 start of combo product (by Dec 31, 2027); $9.65 for FDA approval of combo (by Dec 31, 2031); $6.40 for FDA approval of MET-097i (by Dec 31, 2029).
- Stockholders approved Merger Agreement: 95,071,667 votes for, 20,655 against, 87,802 abstained.
- Common stock delisted from Nasdaq; company will file Form 15 to deregister and suspend SEC reporting.
- Board replaced: prior directors resigned; Deborah Baron and Alison O'Neill appointed; all officers ceased service.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2040807/000119312525280387/0001193125-25-280387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2040807/000119312525280387/d161976d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-280387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer